- Home
- DSL vs RCUS Comparison
DSL vs RCUS Comparison
Compare DSL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- RCUS
- Stock Information
- Founded
- DSL 2013
- RCUS 2015
- Country
- DSL United States
- RCUS United States
- Employees
- DSL N/A
- RCUS N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- RCUS Health Care
- Exchange
- DSL Nasdaq
- RCUS Nasdaq
- Market Cap
- DSL 1.4B
- RCUS 1.2B
- IPO Year
- DSL N/A
- RCUS 2018
- Fundamental
- Price
- DSL $12.34
- RCUS $12.44
- Analyst Decision
- DSL
- RCUS Buy
- Analyst Count
- DSL 0
- RCUS 8
- Target Price
- DSL N/A
- RCUS $20.71
- AVG Volume (30 Days)
- DSL 360.1K
- RCUS 727.5K
- Earning Date
- DSL 01-01-0001
- RCUS 11-05-2025
- Dividend Yield
- DSL 10.71%
- RCUS N/A
- EPS Growth
- DSL N/A
- RCUS N/A
- EPS
- DSL N/A
- RCUS N/A
- Revenue
- DSL N/A
- RCUS $262,000,000.00
- Revenue This Year
- DSL N/A
- RCUS N/A
- Revenue Next Year
- DSL N/A
- RCUS N/A
- P/E Ratio
- DSL N/A
- RCUS N/A
- Revenue Growth
- DSL N/A
- RCUS 6.07
- 52 Week Low
- DSL $10.58
- RCUS $6.50
- 52 Week High
- DSL $13.07
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- DSL 42.91
- RCUS 70.00
- Support Level
- DSL $12.55
- RCUS $11.30
- Resistance Level
- DSL $12.49
- RCUS $12.05
- Average True Range (ATR)
- DSL 0.08
- RCUS 0.58
- MACD
- DSL -0.03
- RCUS 0.05
- Stochastic Oscillator
- DSL 15.41
- RCUS 97.66
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.